Loading...
Persons with hereditary hemorrhagic telangiectasia (HHT; Rendu-Osler-Weber disease) have recurrent episodes of bleeding from telangiectasias in the nose and internal organs. Tranexamic acid is an inhibitor of fibrinolysis that has been reported to decrease bleeding in this disorder.
To examine the efficacy and safety of tranexamic acid in HHT, European investigators conducted a multicenter, randomized, placebo-controlled, double-blind, crossover trial involving 118 patients who received tranexamic acid (1.5 g twice daily) followed by placebo or the opposite sequence; each treatment period was 3 months.
The mean duration of nose-bleeding each month (the primary endpoint) was shorter during treatment with tranexamic acid versus placebo (106 vs.…